Biotech Values

[DewDiligence]

Interview with Cortex's Roger Stoll,
in the Wall Street Transcript:

http://www.cortexpharm.com/pdfs/2-InterviewCOR2004.pdf

This interview, from May, 2004, contains a frank discussion of what went wrong with COR’s initial Ampakine compound, CX-516, and why the follow-on molecule, CX-717, should work a heck of a lot better. A pretty good overview of this promising --and exceptionally cheap-- company in the CNS arena.

It’s instructive to compare this TWST interview with one from last summer (#msg-3202870) to see just what has changed in the ensuing ten months.

[Thanks to ‘apoolfool’ on the Yahoo board.]

P.S. COR has a 30-minute webcast today (Tuesday):
http://biz.yahoo.com/cc/3/43473.html